{"database":"EGA","file_versions":[],"scores":null,"additional":{"omics_type":["Genomics"],"dataset_type":["Illumina HiSeq 2500;"],"full_dataset_link":["https://ega-archive.org/datasets/EGAD00001000997"],"sample_count":["2"],"description":["EGA dataset EGAD00001000997"],"repository":["EGA"],"title":["Chronic lymphocytic leukemia driven by paradoxical ERK activation during BRAF inhibitor treatment"],"pubmed_abstract":["Patients with BRAFV600E/K-driven melanoma respond to the BRAF inhibitor vemurafenib due to subsequent deactivation of the proliferative RAS/RAF/MEK/ERK pathway. In BRAF WT cells and those with mutations that activate or result in high levels of the BRAF activator RAS, BRAF inhibition can lead to ERK activation, resulting in tumorigenic transformation. We describe a patient with malignant melanoma who developed chronic lymphocytic leukemia (CLL) in the absence of RAS mutations during vemurafenib treatment. BRAF inhibition promoted patient CLL proliferation in culture and in murine xenografts and activated MEK/ERK in primary CLL cells from additional patients. BRAF inhibitor-driven ERK activity and CLL proliferation required B cell antigen receptor (BCR) activation, as inhibition of the BCR-proximal spleen tyrosine kinase (SYK) reversed ERK hyperactivation and proliferation of CLL cells from multiple patients, while inhibition of the BCR-distal Bruton tyrosine kinase had no effect. Additionally, the RAS-GTP/RAS ratio in primary CLL cells exposed to vemurafenib was reduced upon SYK inhibition. BRAF inhibition increased mortality and CLL expansion in mice harboring CLL xenografts; however, SYK or MEK inhibition prevented CLL proliferation and increased animal survival. Together, these results suggest that BRAF inhibitors promote B cell malignancies in the absence of obvious mutations in RAS or other receptor tyrosine kinases and provide a rationale for combined BRAF/MEK or BRAF/SYK inhibition."],"pubmed_title":["BRAF inhibitor-associated ERK activation drives development of chronic lymphocytic leukemia."],"pubmed_authors":["Yaktapour Niuscha N, Meiss Frank F, Mastroianni Justin J, Zenz Thorsten T, Andrlova Hana H, Mathew Nimitha R NR, Claus Rainer R, Hutter Barbara B, Fröhling Stefan S, Brors Benedikt B, Pfeifer Dietmar D, Pantic Milena M, Bartsch Ingrid I, Spehl Timo S TS, Meyer Philipp T PT, Duyster Justus J, Zirlik Katja K, Brummer Tilman T, Zeiser Robert R"],"name_synonyms":["Vasp, VASP, Data Set., DmelCG15112, ENHANCER OF ATNSI ACTIVITY, MENA, NDPP1, l(2)02029, Enb, enb, ENA, Ena, CG15112, ENA/VASP"],"description_synonyms":["Kinase Kinases, Ly-A, RAS, Ras, DmErk, extracellular signal-regulated kinase activity, l(1)G0098, pp44mapk, DSORT, Tyro5, MEK1/2, raf, Ras-1, prevention, ras, c-ras2, LeMPK3, Lyt-1, p44mpk, Dp38, B4, monocyte differentiation antigen CD14, Whole Transcriptome, Transcriptome Sequencing, AA120551, Ly-1, Kinase, B8, SAPK2, SEM, Sem, lymphocyte antigen 1, treatment, MAP-k, Divorced, thymus nucleic acid, Draf-1, MAPK-ERK Kinases, pp42, EK5, Dsor2, Divorces, myeloid cell-specific leucine-rich glycoprotein, DSor1, DSOR1, sem, D-raf1, Map Kinase, Map Kinase Kinase, adult chronic leukemia, CG1799, single organism signaling, ERK-A, preventive therapy, dpERK, dpErk, Ras2, RAS2, l(1)phl, Ras1, RAS1, Exome, ERK-2, DmMAPK, Malignant Melanomas, PMK-2, dp-ERK, PMK-1, lymphoplasmacytic leukemia, PMK-3, dRas85D, MAP Kinase Kinases, pMAPK, pMapK, DMEK-1, chronic lymphatic leukemia, ras1, desoxyribose nucleic acid, ras2, BcDNA:RE36103, EK1-1, Complete Transcriptome, DmERKA, l(1)pole hole, rl/MAPK, T-cell surface antigen Leu-12, Hras-1, Dm Ras1, l(2)41Ac, l(1)polehole, D-raf, C78273, RasI, CT34260, dpERk, MAPK-ERK, differentiation antigen CD19, Ficoll WBC Isolation, ds DNA, Whole Exome Sequencing, SAPK, Afr-1, DNA, EG:BACH48C10.3, Harvey-ras, AA473386, Hras1, MAPK Kinases, 9030612K14Rik, CLL, Cll, atypia, MEKs, DNS, (Deoxyribonucleotide)n, dRas, MAPK-ERK Kinase, CG1167, number, chronic LYMPHOCYTIC, 12559, H-ras, DRaf, DRAS1, DRas2, IMPDH, AFR1, Afr1, draf, LD06825, EK2-1, Dras2, Dras1, cll, melanoma (disease), CML, AA407128, D-Ras, Deoxyribonucleic Acid, urinary form, Kras-2, Prkm1, atypical, IMPdH, Ha-ras, D-RAF, D-Raf, MAP, Map, ERK, Erk, Dras, PRKM1, ras 1, PRKM2, mKIAA0854, Complete, Exome Sequencings, raspberry/impd, Naevocarcinoma, PCBC, C87398, Double Stranded, Phl, Deoxyribonucleic acid, MEK 7, Ras[V12], EK3-4, Sequencing, erk, DRas, DRas85D/Ras, Dmras64B, Whole Exome, Kinase Kinase, Whole, Draf, rll, (Deoxyribonucleotide)m, STK26, SOR, Sor, p38-2, myelin basic protein kinase activity, CG7937, leukemia, DRT, Complete Exome Sequencings, whole blood, MAP-ERK, DNAn+1, raf-1, stress-activated kinase activity, Chronic Lymphocytic Leukemia, lymphoplasmacytic leukaemia, MAP-2 kinase activity, 311, BRAF1, LEU1, defective, sor, D-ras-1, chronic, Cell, AW495831, MK, E(faf), Exome Sequencing, DmelCG1167, 93Bal, MAPK ERK Kinases, Malignant Melanoma, stress-activated protein kinase activity, B-lymphocyte surface antigen B4, mapk2, mapk1, S35097, MEK, Mek, MAP Kinase, RAS85D, c15, Dmras85D, CG12559, Peripheral Blood, l(1)9Eb, Mitogen Activated Protein Kinase Kinases, prophylaxis, P42MAPK, DmelCG7937, Separations, dpERK1, mek, cardinality., Reticuloendothelial System, l(1)polehole/draf, AU018647, signalling process, RG 7204, dpMAPK, Braf2, control, Desoxyribonukleinsaeure, ph, General activity, SAP kinase activity, Ras1/RAs85D, dsor1, MAP-ERK Kinase, Activity, Blood, Mpk2, D-MEK/Dsor, c-rasHa, p42mapk, E(sev)3C, PRKMK7, CG11485, SR2-1, Ly-12, melanoma, Su(Raf)34B, mitogen-activated protein kinase activity, prevention and control, mpk1, RG7204, D-Ras1, chronic lymphatic, Erk/Map kinase, RTK, reference sample, B-cell chronic lymphocytic leukemia, Complete Exome Sequencing, Whole Transcriptome Sequencing, l(1)G0436, DERK-A, ras85B, CD19, ras85D, E(sina)7, Rl, CD14, adult chronic leukaemia, T1, 9930012E13Rik, preventive measures, MP kinase activity, DERK, D-ras-2, C230098H17, disease management, Therapies, MBP kinase II activity, Double-Stranded DNA, dERK, D6Ertd631e, deoxyribonucleic acids, DNAn, dSor1, chronic lymphatic leukaemia, Therapy, l(3)s1747, B-RAF1, MAP kinase 2 activity, SAPKK4, aberrant, sor/MEK1, D-sor-1, Mapk, Ki-ras, KIAA0854, DSor, Erk1, ERK1, ERK2, mapk1a, Erk2, Double-Stranded, DRODSOR1, (Deoxyribonucleotide)n+m, ZHX2, Melanoma, p41mapk, mapk1b, MapK, MAPK, lymphocyte antigen T1/Leu-1, p21[Ras1], dRas1, dRAS1, lymphocytic, DRaf1, Dras85D, Mitogen Activated Protein Kinase Kinase, erk2, dSor, mapk, ras-2, l(1)G0475, ERKa, RAFB1, l(1)G0351, LD02673, MAP ERK Kinase, BcDNA:RE08694, DmelCG1799, c-Ha-ras, l(2R)EMS45-39, Draf1, D-ras1, l(1)G0238, D-ras2, raf1, CAPB, AA387315, DmelCG12559, C-ras1, p38, Dras64B, Treatments, C-ras2, l(3)06677, DpErk, DpERK, l(1)G0002, dMEK, ErkA, 1-Propanesulfonamide, ERKA, l(1)G0482, Patient, c-H-ras, p41, PBMCs, l(1)G0127, p40, Differentiation antigen CD19, C110, Dsor, chronic lymphocytic leukaemia, R05185426, Transcriptome Sequencings, MAPK Kinase, CVID3, pERK, rafl, Lymphocyte antigen T1|Leu-1, CIB8, MAPKK7, RasV12, GroupII, Complete Exome, Kras2, NS7, DmelCG9375, Malignant, presence, B-cell chronic lymphocytic leukaemia, Deoxyribonucleic acids, Monocyte differentiation antigen CD14, D-mek, PLX 4032, l(1)G0388, PLX4032, Hek5, Zelboraf, B-cell chronic lymphoid leukemia, PBMC, Dmek, p42-MAPK, JNKK2, Separated, l(1)G0380, Raf1, CG15793, p21B, WES, MAPK ERK Kinase, dras1, Dm-ras-64B, MAPKKs, DmelCG2845, MKK7, xp42, D-sor, l(1)G0391, p42 mitogen-activated protein kinase activity, CG18732, ATP:protein phosphotransferase (MAPKK-activated) activity, Ect5, Ras 85D, l(1)raf, Clients, 4-difluorophenyl)-, DmERK-A, ras-l, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2, D-Mek, D-MEK, Controlled, l(1)G0056, Controlling, ert1, Mitogen-Activated Protein Kinase Kinase, CG9375, malignant, prkm2, prkm1, CT39192, K-ras, l(1)2Fe, Client, MEK/Dsor1, p38delta, Melanomas, count in organism, fs(3)05703, Raf/phl, Myeloid cell-specific leucine-rich glycoprotein, EP(X)1093, MBP kinase I activity, membrane-bound form, B-raf, ds-DNA, AI929937, D-SOR, D-Sor, Xp42, DmelCG15793, small lymphocytic lymphoma, Separation, ly-1, Complete Transcriptome Sequencing, MAPKK, Kinases, mitogen activated kinase activity, RG-7204, Su(Raf)2B, SAPKK-4, patient, EY2-2, MAPK2, l(1)ph, Su(tor)3-2, 11-29, Ficoll gradient, Hox11-311, D-ERK, Therapeutic, Braf-2, ERT1, EPHT3, 3-b)pyridin-3-yl)carbonyl)-2, Treatment, malignant melanoma, CD5, Raf, RAF, MAP kinase 1 activity, CG2845"],"pubmed_title_synonyms":["CLL Lymphoplasmacytoid Lymphomas, DmErk, extracellular signal-regulated kinase activity, pp44mapk, Chronic B-Cell, single-organism developmental process, Tyro5, Mpk2, postnatal development, Chronic B-Lymphocytic, p42mapk, growth and development, Lymphatic Leukemia, SR2-1, B Cell, Small, LeMPK3, p44mpk, Dp38, AA120551, mitogen-activated protein kinase activity, Lymphoplasmacytoid Lymphoma, Chronic Lymphocytic Leukemias, SAPK2, mpk1, SEM, Sem, Lymphomas, chronic lymphatic, MAP-k, Erk/Map kinase, B-cell chronic lymphocytic leukemia, pp42, Small-Cell Lymphomas, EK5, DERK-A, CLL Lymphoplasmacytoid Lymphoma, Plasmacytoid, Dsor2, Small Lymphocytic Lymphoma, Well-Differentiated Lymphocytic Lymphoma, E(sina)7, B-Lymphocytic Leukemia, B Cell., sem, Rl, 9930012E13Rik, Lymphoblastic Leukemias, MP kinase activity, DERK, Chronic Lymphatic Leukemias, C230098H17, MBP kinase II activity, dERK, Malignancies, D6Ertd631e, associated, chronic lymphatic leukaemia, ERK-A, B-Cell Chronic Lymphocytic Leukemia, B-RAF1, MAP kinase 2 activity, dpERK, dpErk, Mapk, B Cell Malignancy, ERK-2, Erk1, ERK1, ERK2, mapk1a, Erk2, DmMAPK, PMK-2, Low-Grade B-Cell Malignancies, dp-ERK, PMK-1, lymphoplasmacytic leukemia, PMK-3, p41mapk, mapk1b, MapK, MAPK, B-Cell Malignancies, pMAPK, pMapK, B Lymphocytic Leukemia, B Cell Chronic Lymphocytic Leukemia, chronic lymphatic leukemia, B Cell Leukemia, lymphocytic, erk2, mapk, activation, Lymphoblastic Leukemia, ERKa, RAFB1, DmERKA, Lymphatic Leukemias, rl/MAPK, BcDNA:RE08694, Drives, Well-Differentiated Lymphocytic Lymphomas, l(2R)EMS45-39, CAPB, AA387315, DmelCG12559, Disrupted In B-Cell Malignancy, p38, Chronic Lymphoblastic, l(2)41Ac, Chronic Lymphoblastic Leukemias, Low-Grade B-Cell Malignancy, C78273, DpErk, DpERK, ErkA, ERKA, CT34260, dpERk, antagonists and inhibitors, Lymphoplasmacytoid, p41, CLL Lymphoplasmacytoid, p40, Lymphoma, SAPK, chronic lymphocytic leukaemia, AA473386, pERK, Small Lymphocytic Lymphomas, 9030612K14Rik, Lymphoplasmacytoid Lymphomas, CLL, Chronic B-Cell Leukemia, GroupII, Lymphocytic Leukemia, B-Lymphocytic Leukemias, 12559, chronic LYMPHOCYTIC, NS7, B-Cell, B-cell chronic lymphocytic leukaemia, EK2-1, Hek5, AA407128, B-cell chronic lymphoid leukemia, Prkm1, Chronic B-Cell Leukemias, Well-Differentiated Lymphocytic, p42-MAPK, Well Differentiated, Low-Grade, ERK, Erk, PRKM1, Lymphocytic, PRKM2, Leukemia, Malignancy, xp42, PCBC, C87398, inhibiteur, Small-Cell Lymphoma, p42 mitogen-activated protein kinase activity, CG18732, ATP:protein phosphotransferase (MAPKK-activated) activity, erk, Diffuse, inhibidor, Disrupted In B Cell Malignancy, Chronic, rll, DmERK-A, Diffuse Well Differentiated Lymphocytic Lymphoma, Chronic B-Lymphocytic Leukemias, STK26, p38-2, Chronic Lymphocytic, Diffuse Well-Differentiated Lymphocytic Lymphoma, Low Grade, myelin basic protein kinase activity, inhibitors, leukemia, ert1, DRT, Small Cell, prkm2, stress-activated kinase activity, Chronic Lymphocytic Leukemia, prkm1, CT39192, Chronic B-Lymphocytic Leukemia, lymphoplasmacytic leukaemia, B-Cell Malignancy, MAP-2 kinase activity, BRAF1, inhibitor, Chronic Lymphoblastic Leukemia, Leukemias, chronic, B-Cell Leukemia, p38delta, development, Well-Differentiated, Chronic Lymphatic, Small Cell Lymphoma, stress-activated protein kinase activity, mapk2, mapk1, Lymphocytic Leukemias, MBP kinase I activity, B-raf, Low-Grade B-Cell, Xp42, antagonists, Chronic Lymphatic Leukemia, small lymphocytic lymphoma, CG12559, Lymphocytic Lymphomas, mitogen activated kinase activity, P42MAPK, Su(Raf)2B, B-Cell Leukemias, dpERK1, postnatal growth, Lymphoblastic, EY2-2, Small Lymphocytic, MAPK2, Small-Cell, AU018647, D-ERK, Lymphocytic Lymphoma, Braf-2, dpMAPK, Braf2, ERT1, EPHT3, growth, SAP kinase activity, MAP kinase 1 activity"],"pubmed_abstract_synonyms":["Kinase Kinases, Brutons Tyrosine Kinase, para Tyrosine, RAS, Ras, DmErk, extracellular signal-regulated kinase activity, B Cells, l(1)G0098, pp44mapk, DSORT, Tyro5, Laboratory, B cell, MEK1/2, raf, TRANSPL HETEROL, Ras-1, House Mouse, Spleen, Mutations, Case Fatality Rates, Death Rates, ras, c-ras2, LeMPK3, GTPBP7, p44mpk, Cultural, Antigen, BCR, Dp38, CG40494, AA120551, Kinase, Excess Mortalities, SAPK2, SEM, Sem, Animalia, MAP-k, treatment, ethnicity, p72-Syk, Draf-1, MAPK-ERK Kinases, pp42, EK5, 2-amino-3-(4-hydroxyphenyl)propanoic acid, 3-(p-Hydroxyphenyl)alanine, Dsor2, B Cell Progenitor Kinase, Y, DSor1, DSOR1, sem, D-raf1, Map Kinase, AI853148, Map Kinase Kinase, Xenotransplantations, adult chronic leukemia, Age-Specific Death Rate, CG1799, ERK-A, Guanosine, dpERK, dpErk, Ras2, RAS2, l(1)phl, Ras1, RAS1, B Lymphocytes, animalia, ERK-2, CASP14, Crude Death, DmMAPK, Malignant Melanomas, PMK-2, para-Tyrosine, dp-ERK, PMK-1, lymphoplasmacytic leukemia, PMK-3, Cultural Background, Bruton Tyrosine Kinase, Cultures, dRas85D, MAP Kinase Kinases, pMAPK, pMapK, DMEK-1, chronic lymphatic leukemia, ras1, PCK, ras2, activation, BcDNA:RE36103, AI561783, EK1-1, DmERKA, Xenotransplantation, l(1)pole hole, rl/MAPK, whole organism, Cultural Beliefs, death rate, Caspase-14 subunit p10, Hras-1, Swiss Mouse, Dm Ras1, l(2)41Ac, Caspase-14 subunit p19, l(1)polehole, exposed, D-raf, C78273, L isomer, RasI, CT34260, Mortality Rate, dpERk, antagonists and inhibitors, MAPK-ERK, B-Lymphocyte, Proliferation, Koerper, SAPK, Mouse, L-Tyrosine, Afr-1, EG:BACH48C10.3, Mortality Determinant, Harvey-ras, AA473386, Hras1, MAPK Kinases, 9030612K14Rik, CLL, Cll, GTP, 3.4.22.-, MEKs, dRas, MAPK-ERK Kinase, 5133400C09Rik, CG1167, 12559, chronic LYMPHOCYTIC, Excess, H-ras, DRaf, DRAS1, mini-ICE, DRas2, IMPDH, Crude Mortality Rate, AFR1, Afr1, draf, LD06825, EK2-1, Age-Specific Death, Dras2, Dras1, cll, melanoma (disease), CML, Rate, Determinant, AA407128, D-Ras, Kras-2, Prkm1, Mus musculus domesticus, Case Fatality, Spleen tyrosine kinase, IMPdH, Ha-ras, D-RAF, D-Raf, MAP, Map, Backgrounds, Spleen Tyrosine, ERK, Erk, DmelCG40494, Dras, PRKM1, ras 1, Differential Mortality, PRKM2, mKIAA0854, Excess Mortality, p72Syk, raspberry/impd, proliferating, Naevocarcinoma, absent from organism, PCBC, C87398, Phl, Cultural Relativisms, PHL, MEK 7, Ras[V12], EK3-4, erk, DRas, DRas85D/Ras, B-cell progenitor kinase, Dmras64B, extruding from, Kinase Kinase, Crude Death Rates, Customs, Draf, rll, STK26, Tyrosin, SOR, Sor, p38-2, myelin basic protein kinase activity, CG7937, Heterologous, inhibitors, leukemia, ALL, DRT, Mortality Decline, MAP-ERK, body, raf-1, Agammaglobulinaemia Tyrosine, stress-activated kinase activity, Chronic Lymphocytic Leukemia, lymphoplasmacytic leukaemia, MAP-2 kinase activity, 311, BRAF1, Bruton's Tyrosine Kinase, whole body, sor, D-ras-1, Cultural Backgrounds, backward, Cell, chronic, MK, E(faf), Case Fatality Rate, DmelCG1167, p72syk, SYK Tyrosine Kinase, XENOTRANSPL, 93Bal, MAPK ERK Kinases, tirosina, Malignant Melanoma, stress-activated protein kinase activity, mapk2, PEPCK-C, mapk1, S35097, MEK, Mek, MAP Kinase, Death, Sykb., BPK, RAS85D, Death Rate, c15, Dmras85D, CG12559, l(1)9Eb, Mitogen Activated Protein Kinase Kinases, RATPEPCK, underdeveloped, increased number, P42MAPK, DmelCG7937, dpERK1, mek, Kinase EMB, Bursa-Equivalent Lymphocyte, House Mice, l(1)polehole/draf, Differential, AU018647, RG 7204, dpMAPK, Braf2, Decline, Relativisms, ph, Relativism, Cultural Relativism, General activity, SAP kinase activity, Differential Mortalities, reversed, Ras1/RAs85D, dsor1, MAP-ERK Kinase, Activity, Bruton's, Triphosphate, Heterograft, Bursa-Dependent Lymphocytes, Mpk2, Mus domesticus, D-MEK/Dsor, c-rasHa, p42mapk, E(sev)3C, CASP-14, PRKMK7, CG11485, SR2-1, Background, Tier, melanoma, Bruton's Tyrosine, Su(Raf)34B, mitogen-activated protein kinase activity, Pepck, mpk1, RG7204, D-Ras1, chronic lymphatic, BCR1, increased, Erk/Map kinase, RTK, B-cell chronic lymphocytic leukemia, Crude Mortality Rates, l(1)G0436, DERK-A, hypoplasia, ras85B, Swiss Mice, ras85D, E(sina)7, Rl, adult chronic leukaemia, 9930012E13Rik, MP kinase activity, DERK, D-ras-2, C230098H17, B lymphocyte, CFR Case Fatality Rate, Tyr, disease management, MBP kinase II activity, Therapies, dERK, D6Ertd631e, dSor1, chronic lymphatic leukaemia, ATK, Sykb, Therapy, l(3)s1747, B-RAF1, MAP kinase 2 activity, SAPKK4, sor/MEK1, D-sor-1, Mapk, Ki-ras, KIAA0854, mouse, 2-Amino-3-(p-hydroxyphenyl)propionic acid, DSor, Erk1, ERK1, ERK2, mapk1a, Erk2, Guanosine 5'-(tetrahydrogen triphosphate), DRODSOR1, results, Crude Mortality, Tyrosine, ZHX2, D22S662, Syk, SYK, Agammaglobulinaemia, Mortality, Melanoma, p41mapk, mapk1b, MapK, MAPK, Mini-ICE, Bruton tyrosine kinase, p21[Ras1], dRas1, dRAS1, lymphocytic, DRaf1, Dras85D, Mitogen Activated Protein Kinase Kinase, erk2, Heterologous Transplantations, dSor, mapk, ras-2, l(1)G0475, Xenograft, Mus musculus, ERKa, RAFB1, l(1)G0351, absence, LD02673, MAP ERK Kinase, BcDNA:RE08694, Transplantation, DmelCG1799, c-Ha-ras, l(2R)EMS45-39, Draf1, mice, D-ras1, l(1)G0238, D-ras2, raf1, CAPB, L-isomer, AA387315, DmelCG12559, C-ras1, p38, Mortalities, Xenografts, Dras64B, MICE, C-ras2, Treatments, CG17960, l(3)06677, Tyrosine Kinase, Agammaglobulinemia tyrosine kinase, domesticus, DpErk, DpERK, l(1)G0002, dMEK, ErkA, 1-Propanesulfonamide, ERKA, l(1)G0482, Crude Death Rate, Patient, c-H-ras, p41, l(1)G0127, p40, C110, Dsor, chronic lymphocytic leukaemia, R05185426, MAPK Kinase, pERK, accessory, rafl, Proliferating, Dmel_CG00000, MAPKK7, RasV12, GroupII, Spleen Tyrosine Kinase, Mortality Declines, Kras2, NS7, DmelCG9375, Transplantations, Malignant, mortality measurement, supernumerary, B-cell chronic lymphocytic leukaemia, D-mek, heterologous transplantation, Mortality Determinants, PLX 4032, l(1)G0388, Crude, PLX4032, Hek5, CG17617, reduced, Zelboraf, House, B-cell chronic lymphoid leukemia, Dmek, rhoGAP1A, p42-MAPK, tiny, Animal, JNKK2, l(1)G0380, Mice, Raf1, CG15793, p21B, B-cell, MAPK ERK Kinase, dras1, Dm-ras-64B, MAPKKs, DmelCG2845, Swiss, D22S11, MKK7, xp42, inhibiteur, Heterografts, metazoa, EG:23E12.5, D-sor, Age-Specific, l(1)G0391, p42 mitogen-activated protein kinase activity, CG18732, EG:23E12.2, ATP:protein phosphotransferase (MAPKK-activated) activity, Ect5, Ras 85D, 2.7.10.2, inhibidor, L Tyrosine, l(1)raf, time of survival, Clients, Mortality Rates, mortality rate, 4-difluorophenyl)-, DmERK-A, culture, ras-l, N-(3-((5-(4-chlorophenyl)-1H-pyrrolo(2, D-Mek, D-MEK, Age Specific Death Rate, l(1)G0056, small, ert1, Mitogen-Activated Protein Kinase Kinase, CG9375, malignant, exits through, prkm2, prkm1, CT39192, inhibitor, K-ras, l(1)2Fe, Client, MEK/Dsor1, p38delta, Melanomas, fs(3)05703, Raf/phl, survival, Mus, EP(X)1093, CG40453, Metazoa, MBP kinase I activity, B-raf, AI929937, Determinants, D-SOR, D-Sor, Xp42, antagonists, DmelCG15793, Rates, small lymphocytic lymphoma, MAPKK, Kinases, mitogen activated kinase activity, RP11-108K14.2, RG-7204, Su(Raf)2B, SAPKK-4, HETEROL TRANSPL, EY2-2, patient, MAPK2, l(1)ph, Age-Specific Death Rates, Su(tor)3-2, 11-29, Laboratory Mice, present in greater numbers in organism, Hox11-311, D-ERK, Braf-2, Therapeutic, ERT1, EPHT3, 3-b)pyridin-3-yl)carbonyl)-2, malignant melanoma, Treatment, Raf, RAF, SYK Tyrosine, mKIAA3017, B-lymphocyte, Laboratory Mouse, MAP kinase 1 activity, CG2845"],"additional_accession":[]},"is_claimable":false,"name":"ena-DATASET-DKFZ-IBIOS-29-08-2014-08:27:40:831-1015 - samples","description":"Whole-exome sequencing of a chronic lymphocytic leukemia (CLL) developed during vemurafenib treatment of a patient with malignant melanoma. Peripheral blood mononuclear cells were separated by Ficoll gradient centrifugation. DNA was extracted from highly purified (>97%) CD19+CD5+ cells obtained from the patient while being under BRAF inhibition versus CD14+ germline control cells (>90% purity). No alterations that could be linked to aberrant RAS activity or paradoxical RAF/MEK/ERK signaling could be identified in the CLL, which shows characteristic copy number alterations.","dates":{"updated":"2017-07-26 15:39:25"},"accession":"EGAD00001000997","cross_references":{"TAXONOMY":["9606"],"pubmed":["25329694"],"EGA":["EGAC00001000452","EGAS00001000948"]}}